Table of Contents
Will Zymergen stock go up?
Zymergen Inc (NASDAQ:ZY) The 3 analysts offering 12-month price forecasts for Zymergen Inc have a median target of 3.00, with a high estimate of 4.00 and a low estimate of 2.00. The median estimate represents a +145.90% increase from the last price of 1.22.
What happen to ZY stock?
Zymergen (ZY) Reports Q1 Loss, Tops Revenue Estimates Zymergen (ZY) delivered earnings and revenue surprises of 1.41% and 57.08%, respectively, for the quarter ended March 2022.
Is ZY a good buy?
Out of 7 analysts, 0 (0%) are recommending ZY as a Strong Buy, 0 (0%) are recommending ZY as a Buy, 4 (57.14%) are recommending ZY as a Hold, 2 (28.57%) are recommending ZY as a Sell, and 1 (14.29%) are recommending ZY as a Strong Sell.
Why is Zymergen stock falling?
Summary. Zymergen went public in April 2021, raising around $500 million in an IPO. The firm designs advanced materials technologies to improve manufacturing processes. ZY has been decimated by the market after no revenue in 2021/2022 and the sudden departure of its CEO.
Should I sell Zymergen?
8 Wall Street equities research analysts have issued “buy,” “hold,” and “sell” ratings for Zymergen in the last twelve months. There are currently 3 sell ratings and 5 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should “hold” Zymergen stock.
What happened at Zymergen?
In November 2021, Zymergen announced that it had abandoned the production of Hyaline, and would be focusing on drug and vaccine development. The company’s highly publicized difficulties in bringing its projected products to market and has drawn comparisons to other biotechnology companies such as Amyris and Theranos.
What is going on with Zymergen?
In April 2020, the company launched Hyaline, which Zymergen claimed in its prospectus as a $1 billion market opportunity. But with the pandemic disrupting global supply chains, the company laid off around 10% to 15% of its workforce a month later, according to a former Zymergen employee who was let go during this time.
Is Zymergen going out of business?
Based on the latest financial disclosure, Zymergen has a Probability Of Bankruptcy of 67%. This is 51.11% higher than that of the Basic Materials sector and 60.33% higher than that of the Specialty Chemicals industry. The probability of bankruptcy for all United States stocks is 68.21% lower than that of the firm.
Who invested in Zymergen?
The round welcomes new investors Goldman Sachs and Hanwha Asset Management, as well as returning investors, DCVC (Data Collective), True Ventures, Two Sigma Ventures, DFJ and Innovation Endeavors.
What’s going on with Zymergen?
Synthetic biology company Zymergen plunges 68% after saying product revenue will be ‘immaterial’ in 2022, removing CEO. Zymergen went public at $31 a share in April and traded as high as $48.50, valuing the company at $4.8 billion.
Is Zymergen public?
When Zymergen went public on April 22, 2021, investors ignored the red flags in its prospectus. Less than four months later, it announced that its CEO was out and product revenue would be “immaterial” in 2022.
What is zymergen’s (Zym) price potential for the next year?
Their forecasts range from $6.50 to $13.00. On average, they anticipate Zymergen’s stock price to reach $9.33 in the next year. This suggests a possible upside of 198.2% from the stock’s current price.
What is the upside for zymergen’s stock?
Their forecasts range from $6.50 to $13.00. On average, they anticipate Zymergen’s stock price to reach $9.33 in the next year. This suggests a possible upside of 198.2% from the stock’s current price. View analysts’ price targets for Zymergen or view top-rated stocks among Wall Street analysts.
Why are zymergen shares soaring today?
Rebounding from the 16% slide that they experienced last week, shares of Zymergen (NASDAQ: ZY) are soaring today as investors learn of an insider’s significant acquisition of the company’s stock.
What is the zymergen company known for?
Zymergen’s platform is used to discover novel molecules used to enable unique material properties. The company was incorporated in 2013 and is based in Emeryville, California. Zymergen has received a consensus rating of Hold.